Title: Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic
treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis
Version: 6 Date: 05 Mar 2022
Reviewer's report:
Authors have already revised their paper according to the comments from editor and reviewers.
I think they did a great job. I have no more comments.
Title: Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic
treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis
Version: 6 Date: 05 Mar 2022
Reviewer's report:
Authors have already revised their paper according to the comments from editor and reviewers.
I think they did a great job. I have no more comments.
Please review this paper.
user
Title: Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic
treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis
Version: 6 Date: 05 Mar 2022
Reviewer's report:
Authors have already revised their paper according to the comments from editor and reviewers.
I think they did a great job. I have no more comments.
assistant